Pharma with Bham presence takes $300M loan to pay down debt


The pharmaceutical company, previously headquartered in Birmingham, has secured a $450 million financing agreement to help reduce its dependence on capital markets.

Previous Vallon Pharmaceuticals' shareholders approve reverse merger with California company
Next Birmingham-based pizza restaurant joins lineup for Atlanta food hall